Caring Ambassadors Program

Hepatitis C Newsletter

March 2012


Clinical Trials, Cohort Studies, Pilot Studies


IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients. Ohnishi M, Tsuge M, Kohno T, et al. J Gastroenterol. 2012 Feb 18. [Epub ahead of print]

A Phase 1, Randomized, Placebo-Controlled, Three-Day, Dose-Ranging Study of GS-5885, an NS5A Inhibitor, in Patients with Genotype 1 Hepatitis C. Lawitz EJ, Gruener D, Hill JM, et al. J Hepatol. 2012 Feb 4. [Epub ahead of print]


Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2 to 6: TMC435-C202, a phase IIa, open-label study. Moreno C, Berg T, Tanwandee T, et al. J Hepatol. 2012 Feb 9. [Epub ahead of print]


Randomized clinical trial: a pilot study investigating the safety and effectiveness of an escalating dose of peginterferon α-2a monotherapy for 48 weeks compared with standard clinical care in patients with hepatitis C cirrhosis. Tanwar S, Wright M, Foster GR, et al. Eur J Gastroenterol Hepatol. 2012 Feb 14. [Epub ahead of print]


A longitudinal cohort study of mucocutaneous drug eruptions during interferon and ribavirin treatment of hepatitis C. Tavakoli-Tabasi S, Bagree A. J Clin Gastroenterol. 2012 Feb;46(2):162-7.


Basic and Applied Science, Pre-Clinical Studies


Soluble serum CD81 is elevated in patients with chronic hepatitis C and correlates with alanine aminotransferase serum activity. Welker MW, Reichert D, Susser S, et al. PLoS One. 2012;7(2):e30796. Epub 2012 Feb 15.


Elevated frequency and function of regulatory T cells in patients with active chronic hepatitis C. Tseng KC, Ho YC, Hsieh YH, Lai NS, Wen ZH, Li C, Wu SF. J Gastroenterol. 2012 Feb 28. [Epub ahead of print]


High prevalence of autoantibodies to C-reactive protein in patients with chronic hepatitis C infection: association with liver fibrosis and portal inflammation. Sjöwall C, Cardell K, Boström EA, et al. Hum Immunol. 2012 Feb 1. [Epub ahead of print]


Sequence Heterogeneity in NS5A of Hepatitis C Virus Genotypes 2a and 2b and Clinical Outcome of Pegylated-Interferon/Ribavirin Therapy. El-Shamy A, Shoji I, Kim SR, et al. PLoS One. 2012;7(2):e30513. Epub 2012 Feb 2.


HIV/HCV Coinfection


Deciphering the Interleukin 28B Variants That Better Predict Response to Pegylated Interferon-α and Ribavirin Therapy in HCV/HIV-1 Coinfected Patients. de Castellarnau M, Aparicio E, Parera M, et al. PLoS One. 2012;7(2):e31016. Epub 2012 Feb 6.


Effects of hepatitis C and HIV on cognition in women: data from the Women's Interagency HIV Study. Crystal H, Kleyman I, Anastos K, et al. J Acquir Immune Defic Syndr. 2012 Feb 1;59(2):149-54.


Important Drug-Drug Interactions in HIV-Infected Persons on Antiretroviral Therapy: An Update on New Interactions Between HIV and Non-HIV Drugs. Tseng A, Foisy M. Curr Infect Dis Rep. 2012 Feb;14(1):67-82.


Impact of IL28B gene polymorphisms on interferon-λ3 plasma levels during pegylated interferon-α/ribavirin therapy for chronic hepatitis C in patients coinfected with HIV.

Rallón NI, Soriano V, Naggie S, et al. J Antimicrob Chemother. 2012 Feb 1. [Epub ahead of print]


Lack of TGFβ Production by Hepatitis C Virus-Specific T Cells during HCV Acute Phase is Associated with HCV Clearance in HIV co-infection. Harfouch S, Guiguet M, Valantin MA, et al. J Hepatol. 2012 Feb 9. [Epub ahead of print]


The Influence of Treatment with Pegylated Interferon-Alfa and Ribavirin on Neutrophil Function and Death in Patients with HIV/HCV Coinfection. Jablonowska E, Wojcik K, Nocun M. Viral Immunol. 2012 Feb 10. [Epub ahead of print]





Complementary and Alternative Medicine


Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. Nimer A, Mouch A. World J Gastroenterol. 2012 Feb 28;18(8):800-5.


Serum Vitamin D Levels Are Not Predictive of the Progression of Chronic Liver Disease in Hepatitis C Patients with Advanced Fibrosis. Corey KE, Zheng H, Mendez-Navarro J, Delgado-Borrego A, Dienstag JL, Chung RT; the HALT-C Trial Group. PLoS One. 2012;7(2):e27144. Epub 2012 Feb 16.


Zinc and liver disease. Mohommad MK, Zhou Z, Cave M, Barve A, McClain CJ. Nutr Clin Pract. 2012 Feb;27(1):8-20.


Epidemiology, Diagnostics, and Miscellaneous Works


The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. Ann Intern Med. 2012 Feb 21;156(4):271-8.


Routine blood tests to predict liver fibrosis in chronic hepatitis C. Hsieh YY, Tung SY, Lee K, et al. World J Gastroenterol. 2012 Feb 28;18(8):746-53.


Hepatitis A virus vaccination in persons with hepatitis C virus infection: consequences of quality measure implementation. Rowe I, Parker R, Armstrong M, Houlihan D, Mutimer D. Hepatology. 2012 Feb 28. doi: 10.1002/hep.25683. [Epub ahead of print]


Future treatment of patients with HCV cirrhosis. Bourlière M, Khaloun A, Wartelle-Bladou C, et al. Liver Int. 2012 Feb;32 Suppl 1:113-9. doi: 10.1111/j.1478-3231.2011.02702.x.

Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important? Halfon P, Sarrazin C. Liver Int. 2012 Feb;32 Suppl 1:79-87. doi: 10.1111/j.1478-3231.2011.02716.x.


Upper limits of normal for alanine aminotransferase activity in the United States population.  Ruhl CE, Everhart JE. Hepatology. 2012 Feb;55(2):447-54. doi: 10.1002/hep.24725.


Depressive and anxiety disorders in chronic hepatitis C patients: Reliability and validity of the Patient Health Questionnaire. Navinés R, Castellví P, Moreno-España J, et al. J Affect Disord. 2012 Feb 10. [Epub ahead of print]


Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk. Litwin AH, Smith BD, Drainoni ML, et al. Dig Liver Dis. 2012 Feb 17. [Epub ahead of print]



Liver Cancer


Transarterial Chemoembolization Plus Sorafenib: A Sequential Therapeutic Scheme for HCV-Related Intermediate-Stage Hepatocellular Carcinoma: A Randomized Clinical Trial. Sansonno D, Lauletta G, Russi S, et al. Oncologist. 2012 Feb 14. [Epub ahead of print]

onteduca V, Sansonno L, Dammacco F.


Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma. Chen L, Zhang Q, Chang W, Du Y, Zhang H, Cao G. Eur J Cancer. 2012 Feb 9. [Epub ahead of print]


Role of fibrogenic markers in chronic hepatitis C and associated hepatocellular carcinoma.

El-Bassiouni NE, Nosseir MM, Madkour ME, et al. Mol Biol Rep. 2012 Feb 9. [Epub ahead of print]